Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001410578-24-001400
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$2.54M | -$5.33M | -$7.04M | -$6.27M |
| EPS Diluted | -$0.60 | -$0.13 | -$0.19 | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end
